bluebird bio Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Thank you, everyone. We are live. Good morning, everyone. Thanks for joining us. I'm pleased to have bluebird bio with us this morning. I'm Salveen Richter, Biotechnology Analyst at Goldman Sachs.
With us from bluebird, we have Nick Leschly, CEO; Chip Baird, CFO; Philip Gregory, CSO; Andrew Obenshain, President, Severe Genetic Diseases; and Nicola Heffron, COO, Oncology.
Questions & Answers
With that, Nick, maybe to start here, bluebird is separating into 2 businesses: one focused on severe genetic diseases and one on oncology and this is anticipated to complete by the end of the year.
To start, can you walk us through where that process stands and what underlies the decision to form 2 separate companies and how you're thinking about the splits in terms of infrastructure here?
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
